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Introduction
The non-valved Baerveldt glaucoma implant (BGI; Abbott Medical Optics, Abbott Park, IL, USA) was introduced in 1990 [1] and is one of the more commonly used implants in moderate to severe glaucoma [2] . The BGI allows aqueous humor in the anterior chamber to bypass the conventional outflow system into a subconjunctival space maintained by the barium-impregnated, silicone rubber plate of the implant [3] .
The BGI is more effective than the valved Ahmed glaucoma implant (AGI) in achieving a lower failure rate and a lower IOP on fewer medications than AGIs at the expense of a higher risk of hypotony [4] .
We had recently performed a comparison of AGIs to Trabectome (Neomedix, Tustin, CA, USA) ab interno trabeculectomies (AIT) by applying propensity score matching to achieve equivalent baseline conditions in both [5] . Although AIT is a microincisional glaucoma surgery that uses plasma to molecularize and aspirate the trabecular meshwork thereby enhancing conventional outflow, our study showed a surprisingly similar IOP reduction that was achieved with fewer medications and fewer complications. In another analysis, we stratified AIT outcomes by glaucoma severity and found that a larger IOP and medication decrease can be achieved in more severe glaucoma [6] [7] [8] . Other investigators have used AIT after failed glaucoma drainage implants [9] or failed trabeculectomy [10, 11] reflecting these observations.
In the present study, we propensity score matched cases of primary BGI and AIT's to directly compare a large and highly effective epibulbar drainage implant to microsurgical trabecular ablation since the traditional indications are too different to allow for prospective randomization.
Methods
This retrospective analysis was approved by the Institutional Review Board of the University of Pittsburgh The cohorts were compared using propensity-score case matching using a genetic algorithm based on age, gender, type of glaucoma, concurrent phacoemulsification, and baseline IOP [12, 13] . Cases of AIT or BGI too different from their counterparts were excluded. The main outcome measure was the mean IOP reduction. Secondary measures were reduction of medications and failure rates. Failure (using criteria of the Tube versus Trabeculectomy trial) [14] was defined as any one of IOP < 6, IOP > 21, or a smaller than 20% decrease from baseline at any two consecutive visits after the 90 day immediate postoperative period, or the need for a subsequent glaucoma procedure.
Surgical Technique
Procedures were performed by the same group of surgeons on comparable patient populations for primary and secondary open angle glaucomas and chronic angle closure. AIT was done before phacoemulsification in combined cases. Approximately 140-160 degrees of nasal TM was ablated under direct gonioscopic view. BGI's were inserted through a fornix-based conjunctival flap in the superotemporal quadrant when possible (92% of cases). The tube was positioned on the anterior surface of the iris. All patients received topical fluoroquinolone and prednisolone acetate 1% four times daily. AIT patients were also given pilocarpine 2% four times daily for 1 month then twice daily for one month. All preoperative glaucoma medications were stopped on the day of surgery and then added back at the discretion of the surgeon. Postoperative visits at day 1, week 1, month 1, month 3, month 6, month 12, month 18, month 24 and month 30 were analyzed.
Statistics
Cases were matched with propensity scores (package "Matching" in R) [15, 16] 
Results
A total of 353 patients met the inclusion criteria. Two hundred and fifty seven eyes were excluded for the occurrence of concurrent surgeries or short follow up. Of the 257 eyes that were excluded, 178 were from the AIT group and 79 were from the BGI group. After propensity score matching 37 eyes from the AIT group and three eyes from the BGI group were excluded. The final cohort included 30 AIT's and 29 BGI's of 59 patients (Fig 1) . Using weighted means, there was no significant difference between the two groups for any of the demographic variables measured including age, gender, type of glaucoma, baseline IOP and the number of medications (all p>0.05) ( Table 1) .
Fig 1. Baerveldt glaucoma drainage implant (BGI) and Trabectome-mediated ab interno trabeculectomy.
The BGI (left and center (red)) is most commonly inserted under the superior and lateral recti muscles. AIT is performed along the nasal angle (temporal ablation with nasal incision depicted in this illustration). The tip of the trabectome has a protective footplate that feeds the trabecular meshwork towards the active and passive electrode where plasma is generated (top right). The molecularized tissue is removed by aspiration and irrigation. As with IOP, there were no statistically significant differences in medication use. The BGI group averaged 2.8±1.1 medications at baseline and 2.4±1.2 at 2.5 years (p=0.17) (Fig 3) . The AIT group averaged 2.3±1.2 medications at baseline, which decreased to 1.5±1.3 years (change: p=0.001; AIT vs BGI: 0.007).
Fig 3. Glaucoma medications in BGI and AIT. in Baerveldt glaucoma drainage implants (BGI) and
Trabectome ab interno trabeculectomies (AIT) were similar during the time under study.
Failure was defined as any one of IOP < 6, IOP > 21, or a smaller than 20% decrease from baseline at any two consecutive visits after the 90 day immediate postoperative period, or the need for a subsequent glaucoma procedure. Success, defined as IOP<21 mmHg, <20% reduction and no reoperation, was achieved in 56% of AIT versus 55% of BGI at 1 year (p>0.05) and 50% versus 52% at 2.5 years (Fig 4) . When we modeled survival with a Cox hazard model and a preoperative IOP variable of 16 mmHg, approximately about 40% survived at 1 year before stabilizing at 30% (Fig 5) . There was no difference between the two groups. When the IOP variable was increased to 21 mmHg, a stable survival of 50% was achieved at two years both AIT and BGI. With baseline IOP set to 26 mmHg, survival was 75% at 500 days and onward for both groups. After AIT, the only complication noted was cystoid macular edema (CME) that occurred in a single case which was combined with phacoemulsification. After BGI, complications included hypotony associated with choroidal detachment past three months (two patients), CME (one patient), conjunctival retraction that required surgical revision (one patient), and aqueous misdirection (one patient).
Discussion
In this study, we found that Trabectome-mediated ab interno trabeculectomy (AIT) and Baerveldt glaucoma drainage devices (BGI) achieved a similar IOP reduction but that BGI had a higher rate of complications compared to AIT. Until recently, AIT had not been directly compared to traditional glaucoma surgeries because the indications and performance were considered too different. Our prior study suggested that AIT and Ahmed glaucoma drainage devices can achieve a comparable pressure reduction when matched carefully on preoperative conditions [5] .
AIT enhances the normal, conventional outflow by removing the trabecular meshwork that constitutes the majority of outflow resistance [17, 18] . In contrast, epibulbar glaucoma drainage implants bypass both the conventional and the uveoscleral route entirely but are subject to encapsidation that is the result of fibrosis and a chronic foreign body reaction [19] . We recently expanded our practice pattern to use AIT as a first surgery for more than mild glaucoma because our studies suggested that AIT can be used after failed trabeculectomy [10] , in narrow angles [20] and for more severe glaucoma [6] [7] [8] . BGIs lowered IOP to a similar extend as trabeculectomies in a randomized controlled trial but had a higher success rate [14] . In the present study the success rates are relatively similar.
This study has several limitations, starting with a relatively small number of patients caused by a limited recruitment window from a tertiary referral center. We excluded cases where AIT is contraindicated, notably active neovascular glaucoma. This could bias the results toward AIT by excluding the most complex cases of glaucoma where IOP reduction with AIT (but not BGI) [21] might not be possible.
We also excluded cases with previous glaucoma surgery which may help explain the relatively high final IOP in the BGI group. The IOP after BGI only decreased from 21.6 to 15 mmHg. Although this is a 31% decrease, lower IOP's were reached in large prospective trials such as the TVT (3 year IOP of 13.3 mmHg, a 47% decrease) [14] , and the pooled Ahmed Baerveldt comparison (3 year IOP of 13.8 mmHg, a 57% decrease) [4] .
Conclusions
Using propensity score matching, AIT resulted in an IOP reduction, final IOP and success rate that was similar to BGI. Patients who underwent AIT required fewer medications and had fewer complications.
